New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
07:44 EDTTHRX, GSKGSK, Theravance announce 'positive' data from two phase III studies
GlaxoSmithKline(GSK) and Theravance,(THRX) announced positive results from two phase III studies, which showed that patients with chronic obstructive pulmonary disease who received the anticholinergic, Incruse Ellipta or umeclidinium 125mcg in addition to Relvar/Breo Ellipta. The studies showed that for the primary endpoint of trough FEV1 at Day 85, the addition of UMEC 62.5mcg or UMEC 125mcg to FF/VI 100/25mcg resulted in a statistically significant improvement in lung function when compared with FF/VI 100/25mcg plus placebo in patients with COPD. The company said, ""With the data reported today, we have further strengthened our understanding of Relvar/Breo Ellipta."
News For GSK;THRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
09:21 EDTGSKOn The Fly: Pre-market Movers
Subscribe for More Information
07:15 EDTGSKAgenus reports GSK ZOE-50 Phase 3 study met primary endpoint
Subscribe for More Information
December 9, 2014
10:23 EDTGSKOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:10 EDTGSKARIAD takeover rumors rekindled, Independent says
Subscribe for More Information
07:44 EDTGSKAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
05:37 EDTGSKGlaxoSmithKline downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill downgraded GlaxoSmithKline to Underperform citing a lack of pipeline catalysts and its belief the European pharma sector is close to fair value.
December 8, 2014
13:32 EDTGSKEpizyme announces results for PRMT5 inhibitor
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use